Report
Martial Descoutures

Moderna : Complete phase 1 results fuel hopes

>Conclusive phase I results - As expected, Moderna and the NIH (National Institutes of Health) reported their full results from phase I of MRNA 1273 vs SARS COV2. Note that we already had interim results from this trial, namely a reassuring overall safety of use on both doses of 50µg and 100µg (significant number of adverse events but none severe) while under 250µg 3 participants presented severe systemic symptoms. The latter dose has since then no longer been retaine...
Underlying
Moderna Inc.

Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Martial Descoutures

Other Reports on these Companies
Other Reports from Oddo BHF

ResearchPool Subscriptions

Get the most out of your insights

Get in touch